483 Roundup: Three Firms Cited for Labeling, Complaints, Safety Problems

Drug GMP Report
A A
The FDA flagged three U.S. facilities for a variety of noncompliances observed by agency investigators during inspections, including issues with labeling, failure to properly handle complaints and reporting of adverse events.

To View This Article:

Login

Subscribe To Drug GMP Report